Current Trials

ACTIVELY ENROLLING STUDIES

ONCOLOGY

BREAST

S1703 - (opened 4/2019): Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer.

A012303 ShortStop - (opened 1/2026): ShortStop- HER2: Shortened Duration Of Adjuvant Therapy In Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade

EA1241 - (opened 2/2026): Extended Clinical Follow Up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol

CLL/SLL

A042302 CLL/SLL - (opened 6/2026): Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclas-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/ SLL)

GI

NRG-GI008 - (opened 1/2026): Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

A022102 - (opened 2/2026): A Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma

S2433 - (opened 2/2026): Randomized Phase III Study of Second-Line Chemotherapy with or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

GENETICS

GH-101 - (opened 3/2025): Genetic Susceptibility and Management of Chronic Disease

LUNG

EA5221:ACHIEVE - (opened 6/2026): Randomized Phase 3 Clinical Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

MULTI-SITE

EVA-43960-01 Cachexia Part B - (opened 4/2026): Qualitative Interviews in Patients With Cachexia and Cancer to Assess the Relevance and Meaningfulness of the FAACT-5IASS, PROMIS Physical Function SF 8c, and 6-Minute Walk Test

QUALITATIVE

ECCO Study - (opened 3/2026): Enhancing Connection and Communication with Community-Based Oncology Practices to Improve Cancer Clinical Trial Recruitment Study

OTHER OPEN ENROLLING TRIALS

SGLT-2 - (opened 6/2026): Metabolic Changes In Response To SGLT-2 Inhibitors Pilot Study

For More Information:

If you would like additional information about the Center for Research, please send your name, company or practice name, address and telephone number to the following address:

Watson Clinic Center for Research

1600 Lakeland Hills Blvd

Lakeland, FL 33805

Attn: Center for Research Director

Phone 863-688-6826 · FAX 863-688-5842

Please indicate which of the following type(s) of information you would like: